ClinicalTrials.gov

History of Changes for Study: NCT03443973
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
Latest version (submitted March 30, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 February 19, 2018 None (earliest Version on record)
2 April 9, 2018 Contacts/Locations and Study Status
3 April 16, 2018 Outcome Measures, Contacts/Locations, Eligibility, Arms and Interventions, Study Design, Study Description, Study Status and Study Identification
4 May 9, 2018 Contacts/Locations, Study Status and Outcome Measures
5 June 11, 2018 Recruitment Status, Contacts/Locations and Study Status
6 June 19, 2018 Contacts/Locations and Study Status
7 July 5, 2018 Contacts/Locations, Outcome Measures and Study Status
8 July 24, 2018 Contacts/Locations, Study Status, Outcome Measures and Arms and Interventions
9 September 12, 2018 Contacts/Locations and Study Status
10 November 7, 2018 Contacts/Locations and Study Status
11 January 9, 2019 Contacts/Locations and Study Status
12 February 27, 2019 Contacts/Locations and Study Status
13 April 8, 2019 Contacts/Locations and Study Status
14 May 9, 2019 Study Status and Contacts/Locations
15 June 17, 2019 Contacts/Locations and Study Status
16 July 18, 2019 Study Status and Contacts/Locations
17 August 20, 2019 Study Status and Contacts/Locations
18 September 23, 2019 Study Status and Contacts/Locations
19 October 24, 2019 Study Status and Contacts/Locations
20 December 4, 2019 Contacts/Locations and Study Status
21 January 9, 2020 Study Status and Contacts/Locations
22 February 5, 2020 Study Status and Contacts/Locations
23 March 12, 2020 Outcome Measures, Study Status, Contacts/Locations, IPDSharing, Eligibility, Study Design and Conditions
24 June 15, 2020 Contacts/Locations, Outcome Measures, Study Status and Study Description
25 August 4, 2020 Contacts/Locations and Study Status
26 September 17, 2020 Recruitment Status, Contacts/Locations and Study Status
27 September 24, 2020 Recruitment Status, Contacts/Locations and Study Status
28 October 23, 2020 Recruitment Status, Contacts/Locations and Study Status
29 January 19, 2021 Study Design, Study Status and Contacts/Locations
30 March 16, 2021 Contacts/Locations and Study Status
31 June 15, 2021 Contacts/Locations, Study Status and Study Design
32 July 13, 2021 Study Status
33 August 12, 2021 Study Status and Contacts/Locations
34 September 6, 2021 Outcome Measures, Study Status, Eligibility and Study Design
35 November 5, 2021 Study Status
36 December 7, 2021 Study Status
37 January 18, 2022 Contacts/Locations and Study Status
38 February 23, 2022 Study Status and Contacts/Locations
39 March 30, 2022 Study Status and Contacts/Locations
Comparison Format:

Scroll up to access the controls

Study NCT03443973
Submitted Date:  February 19, 2018 (v1)

Open or close this module Study Identification
Unique Protocol ID: WN39658
Brief Title: Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
Official Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Prodromal to Mild Alzheimer's Disease
Secondary IDs: 2017-001365-24 [EudraCT Number]
Open or close this module Study Status
Record Verification: February 2018
Overall Status: Not yet recruiting
Study Start: July 31, 2018
Primary Completion: July 1, 2022 [Anticipated]
Study Completion: June 20, 2023 [Anticipated]
First Submitted: February 19, 2018
First Submitted that
Met QC Criteria:
February 19, 2018
First Posted: February 23, 2018 [Actual]
Last Update Submitted that
Met QC Criteria:
February 19, 2018
Last Update Posted: February 23, 2018 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Hoffmann-La Roche
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: Yes
U.S. FDA-regulated Device: No
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with prodromal to mild AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 104. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.
Detailed Description:
Open or close this module Conditions
Conditions: Alzheimer's Disease
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 3
Interventional Study Model: Parallel Assignment
Number of Arms: 2
Masking: Double (Participant, Investigator)
Allocation: Randomized
Enrollment: 750 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Gantenerumab
Gantenerumab will be administered as SC injections with graduate uptitration.
Drug: Gantenerumab
Gantenerumab will be administered as per the schedule specified in the respective arm.
Placebo Comparator: Placebo
Placebo will be administered as SC injections with graduate uptitration.
Drug: Placebo
Placebo matching to gantenerumab will be administered as per the schedule specified in the respective arm.
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Change From Baseline to Week 104 in Clinical Dementia Rating-Sum of Boxes (CDR-SOB) Score
[ Time Frame: Baseline up to Week 104 ]

Secondary Outcome Measures:
1. Change From Baseline to Week 104 in Alzheimer Disease Assessment Scale-Cognition 11 (ADAS-Cog11) Subscale Score
[ Time Frame: Baseline up to Week 104 ]

2. Change From Baseline to Week 104 in Mini-Mental State Examination (MMSE) Total Score
[ Time Frame: Baseline up to Week 104 ]

3. Change From Baseline to Week 104 in Alzheimer Disease Assessment Scale-Cognition 13 (ADAS-Cog13) Subscale Score
[ Time Frame: Baseline up to Week 104 ]

4. Change From Baseline to Week 104 in Verbal Fluency Task Score
[ Time Frame: Baseline up to Week 104 ]

5. Change From Baseline to Week 104 in Functional Activities Questionnaire (FAQ) Score
[ Time Frame: Baseline to Week 104 ]

6. Change From Baseline to Week 104 in Alzheimer Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL) Total Score
[ Time Frame: Baseline up to Week 104 ]

7. Percentage of Participants With Adverse Events (AEs)
[ Time Frame: Baseline up to end of study (up to Week 152) ]

8. Percentage of Participants With Anti-Drug Antibodies (ADA) to Gantenerumab
[ Time Frame: Baseline up to end of study (up to Week 152) ]

9. Plasma Concentration of Gantenerumab
[ Time Frame: Pre-dose (0 hour [hr]) at Baseline (Day 1), Weeks 24, 52, 76; and at Weeks 2, 41, 103, 116, early termination visit (up to Week 152) ]

10. Change From Baseline in Brain Amyloid Load, as Measured by Amyloid Positron Emission Tomography (PET) Scan up to Week 104
[ Time Frame: Baseline up to Week 104 ]

11. Change From Baseline in Brain Tau Load, as Measured by Tau PET Scan up to Week 104
[ Time Frame: Baseline up to Week 104 ]

12. Change From Baseline in Cerebral Spinal Fluid (CSF) Marker of Disease - Amyloid-beta 1-42 (Aβ1-42) up to Week 104
[ Time Frame: Baseline up to Week 104 ]

13. Change From Baseline in CSF Marker of Disease - Total Tau up to Week 104
[ Time Frame: Baseline up to Week 104 ]

14. Change From Baseline in CSF Marker of Disease - Phosphorylated Tau up to Week 104
[ Time Frame: Baseline up to Week 104 ]

15. Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI) up to Week 104
[ Time Frame: Baseline up to Week 104 ]

MRI will be used to assess the effect of treatment on volume of whole brain, ventricles, hippocampus, or other structures.
Open or close this module Eligibility
Minimum Age: 50 Years
Maximum Age: 90 Years
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Key Inclusion Criteria:

  • Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment [MCI])
  • Evidence of the AD pathological process, as confirmed by CSF or amyloid PET scan
  • Demonstrated abnormal memory function
  • MMSE score between 20 and 30 (inclusive)
  • Clinical dementia rating-global score (CDR-GS) of 0.5 or 1.0
  • Availability of a reliable study partner who accepts to participate in study procedures throughout the study duration
  • If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening

Key Exclusion Criteria:

  • Any evidence of a condition other than AD that may affect cognition
  • History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder
  • History or presence of clinically evident vascular disease that in the opinion of the investigator has the potential to affect cognitive function
  • At risk of suicide in the opinion of the investigator
  • Alcohol or substance abuse in past 2 years
  • Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities
  • Any contraindications to brain MRI
  • Unstable or clinically significant cardiovascular, kidney or liver disease
  • Uncontrolled hypertension
Open or close this module Contacts/Locations
Central Contact Person: Reference Study ID Number: WN39658 www.roche.com/about_roche/roche_worldwide.htm
Telephone: 888-662-6728 (U.S. and Canada)
Email: global-roche-genentech-trials@gene.com
Study Officials: Clinical Trials
Study Director
Hoffmann-La Roche
Locations: United States, Arizona
Noesis Pharma Clinical Trials
Phoenix, Arizona, United States, 85032
Mayo Clinic
Scottsdale, Arizona, United States, 85259
United States, California
Fullerton Neurology and Headache Center
Fullerton, California, United States, 92835
Neurology Center of North Orange County
Fullerton, California, United States, 92835
Behavioral Research Specialists, LLC
Glendale, California, United States, 91206
Irvine Center for Clinical Research
Irvine, California, United States, 92614
UCLA - School of Medicine, VA Medical Center
Los Angeles, California, United States, 90073
Pacific Neuroscience Med Grp
Oxnard, California, United States, 93030
Desert Valley Research
Rancho Mirage, California, United States, 92270
University of California, Davis; Alzheimers Disease Center, Department of Neurology
Sacramento, California, United States, 95817
San Francisco Clinical Research Center
San Francisco, California, United States, 94109
Southern California Research LLC
Simi Valley, California, United States, 93065
United States, Connecticut
Associated Neurologists of Southern CT PC
Fairfield, Connecticut, United States, 06824
Yale University School Of Medicine
New Haven, Connecticut, United States, 06510
United States, Florida
Global Medical Institues, LLC; Boynton Beach Medical Research Institute
Boynton Beach, Florida, United States, 33437
Meridien Research
Bradenton, Florida, United States, 34201
Meridien Research
Brooksville, Florida, United States, 34601
Optimus U Corp
Coral Gables, Florida, United States, 33134
Neuropsychiatric Research; Center of Southwest Florida
Fort Myers, Florida, United States, 33912
Allied Biomedical Research Institute, Inc
Miami, Florida, United States, 33155
Renstar Medical Research
Ocala, Florida, United States, 34471
Sensible Healthcare; Ocoee, FL
Ocoee, Florida, United States, 34761
Progressive Medical Research
Port Orange, Florida, United States, 32127
Infinity Clinical Research, LLC
Sunrise, Florida, United States, 33351
United States, Georgia
iResearch Atlanta
Decatur, Georgia, United States, 30030
United States, Illinois
Heathcare Research Network II, LLC
Blue Island, Illinois, United States, 60406
Rush Alzheimer's Disease Cntr.
Chicago, Illinois, United States, 60612
Chicago Research Center, Inc.
Chicago, Illinois, United States, 60634
United States, Indiana
American Health Network Institute, LLC
Avon, Indiana, United States, 46123
United States, Kansas
University of Kansas Medical Centre
Kansas City, Kansas, United States, 66160
Conduct Clinical Trials; Psychiatry Associates of Kansas City
Leawood, Kansas, United States, 66206
United States, Kentucky
Four Rivers Clinical Research Inc.
Paducah, Kentucky, United States, 42003
United States, Maryland
University of Maryland Clinical Neurobehavioral Center
Columbia, Maryland, United States, 21045
United States, Massachusetts
Brigham and Womens Hospital; Center for Alzheimer Research & Treatment
Boston, Massachusetts, United States, 02115
ActivMed Practices and Research
Haverhill, Massachusetts, United States, 01830
United States, Missouri
Center For Pharmaceutical Research
Kansas City, Missouri, United States, 64114
Clinvest Research LLC
Springfield, Missouri, United States, 65807
United States, New Jersey
Memory Enhancement Center of America, Inc.
Eatontown, New Jersey, United States, 07724
NJ Institute for Successful Aging
Stratford, New Jersey, United States, 08084
United States, New York
Integrative Clinical Trials LLC
Brooklyn, New York, United States, 11229
Pioneer Midwood
Brooklyn, New York, United States, 11229
SUNY Upstate Medical University
Syracuse, New York, United States, 13210
United States, North Carolina
Guilford Neurologic Associates
Greensboro, North Carolina, United States, 27401
United States, Ohio
Neuro-Behavioral Clinical Research, Inc.
Canton, Ohio, United States, 44718
United States, Oklahoma
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States, 73112
United States, Pennsylvania
Lehigh Center Clinical Research
Allentown, Pennsylvania, United States, 18104
United States, South Carolina
BG Neurology, LLC
Spartanburg, South Carolina, United States, 29307
United States, Texas
Shepherd Healthcare
Lewisville, Texas, United States, 75067
United States, Utah
Aspen Clinical Research
Orem, Utah, United States, 84058
United States, Washington
Core Clinical Research
Everett, Washington, United States, 98201
Seattle Institute for Biomedical & Clinical Research
Seattle, Washington, United States, 98108
Argentina
Instituto Geriatrico Nuestra Señora de las Nieves
Capital Federal, Argentina, C1427
CEN Centro Especializado en Neurociencias
Córdoba, Argentina, 5000FJF
Instituto Kremer
Córdoba, Argentina, X5004AOA
Instituto de Neurociencias San Agustín S.A.
La Plata, Argentina, 1900
Fundación Scherbovsky
Mendoza, Argentina, 5500
Belgium
AZ Sint Blasius (Dendermonde)
Dendermonde, Belgium, 9200
UZ Gent
Gent, Belgium, 9000
Jessa Zkh (Campus Virga Jesse)
Hasselt, Belgium, 3500
Clinique Saint-Joseph
Liège, Belgium, 4000
Chile
Clinica Portal oriente; Psicomedica
Antofagasta, Chile
Biomedica Research Group
Santiago, Chile, 7500710
Especialidades Medicas LYS
Santiago, Chile, 7560356
Croatia
Clinical Hospital Centre Zagreb;Clinic for Neurology
Zagreb, Croatia, 10000
Denmark
Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken
Aarhus C, Denmark, 8000
Rigshospitalet, Hukommelsesklinikken
København Ø, Denmark, 2100
Odense Universitetshospital, Neurologisk Afd. N;Demensklinikken
Odense C, Denmark, 5000
Finland
University of Eastern Finland
Kuopio, Finland, 70210
CRST Oy
Turku, Finland, 20520
Japan
Yachiyo Hospital
Aichi, Japan, 446-8510
Nagoya Ekisaikai Hospital
Aichi, Japan, 454-8502
National Center for Geriatrics and Gerontology
Aichi, Japan, 474-8511
Fukuoka University Hospital
Fukuoka, Japan, 814-0180
National Hospital Organization Hiroshima-Nishi Medical Center
Hiroshima, Japan, 739-0696
Hyogo Brain and Heart Center at Himeji
Hyogo, Japan, 670-0981
Matsui Dietary and Dementia Clinic
Hyogo, Japan, 673-0891
Nara City Hospital
Nara, Japan, 630-8305
Katayama Medical Clinic
Okayama, Japan, 710-0813
MI Clinic
Osaka, Japan, 560-0004
National Hospital Organization Hizen Psychiatric Center
Saga, Japan, 842-0192
Tokushima Hospital
Tokushima, Japan, 776-8585
Korea, Republic of
Dong-A University Hospital
Busan, Korea, Republic of, 49201
Myongji Hospital
Gyeonggi-do, Korea, Republic of, 10475
Seoul National University Bundang Hospital
Gyeonggi-do, Korea, Republic of, 13620
Bucheon St Mary's hospital
Gyeonggi-do, Korea, Republic of, 14647
Inha University Hospital
Incheon, Korea, Republic of, 22332
Konkuk University Medical Center
Seoul, Korea, Republic of, 05030
Asan Medical Center
Seoul, Korea, Republic of, 05505
Samsung Medical Center
Seoul, Korea, Republic of, 06351
Seoul St Mary's Hospital
Seoul, Korea, Republic of, 06591
Ewha Womans University Mokdong Hospital
Seoul, Korea, Republic of, 07985
Mexico
Unidad de investigacion en salud (UIS); Neurociencias
Ciudad de Mexico, Mexico
Hospital Angeles Culiacan; Neurociencias
Culiacan, Mexico, 80020
Mexico Centre for Clinical Research
Mexico, Mexico, 03100
Hospital Universitario Dr Jose Eleuterio Gonzalez UANL; Depto.de NeurologíaPta.BajaConsulta
Monterrey, Mexico, 64460
AVIX Investigación Clínica S.C
Monterrey, Mexico, 64710
Mexico, Mexico CITY (federal District)
Hospital Español; Servicio de Nuerologia
Ciudad de México, Mexico CITY (federal District), Mexico, 11550
Grupo Medico de Investigacion Clinica Multidisciplinaria
Mexico City, Mexico CITY (federal District), Mexico, 03100
Netherlands
Brain Research Center B.V
Amsterdam, Netherlands, 1081 GN
Poland
Podlaskie Centrum Psychogeriatrii
Białystok, Poland, 15-756
NZOZ Vitamed
Bydgoszcz, Poland, 85-079
KO-MED Centra Kliniczne Lublin II
Lublin, Poland, 20-362
Neurologiczny NZOZ Centrum Leczenia SM; Osrodek Badan Klinicznych
Plewiska, Poland, 62-064
NEURO-CARE Sp. z o.o. Sp. Komandytowa
Siemianowice Śląskie, Poland, 41-100
Senior Sp. Z O.O. Poradnia Psychogeriatryczna
Sopot, Poland, 81-855
mMED Maciej Czarnecki
Warszawa, Poland, 01-697
Pratia S.A.
Warszawawa, Poland, 01-868
NZOZ WCA
Wrocław, Poland, 53-139
Ośrodek Badawczo-Naukowo-Dydaktyczny Chorób Otępiennych UW Medycznego we Wrocławiu SP ZOZ w Ścinawie
Ścinawa, Poland, 59-330
Portugal
Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia
Amadora, Portugal, 2720-276
Hospital de Braga; Servico de Neurologia
Braga, Portugal, 4710-243
HUC; Servico de Neurologia
Coimbra, Portugal, 3000-075
Hospital da Senhora da Oliveira-Guimarães; Serviço de Neurologia
Guimarães, Portugal
Hospital Geral de Santo Antonio; Servico de Neurologia
Porto, Portugal, 4099-001
Puerto Rico
Santa Cruz Behavioral PSC
Bayamon, Puerto Rico, 00961
Instituto De Neurologia Dra. Ivonne Fraga, PSC
San Juan, Puerto Rico, 00918-4502
Dr Michel A. Woodbury, PSC
San Juan, Puerto Rico, 00918
University of Puerto Rico - Medical Science Campus; Internal Medicine
San Juan, Puerto Rico, 00936
Singapore
National University Hospital (NUH); Neuroscience
Singapore, Singapore, 117549
National Neuroscience Institute; Neurology
Singapore, Singapore, 308433
Spain
Hospital del Mar; Servicio de Neurologia
Barcelona, Spain, 08003
Instituto Internacional de Neurociencias Aplicadas (IINA); Servicio de Psiquiatría
Barcelona, Spain, 08006
Fundación ACE; Servicio de Neurología
Barcelona, Spain, 08028
Hospital Universitari Vall d'Hebron; Sevicio de Psiquiatría
Barcelona, Spain, 08035
Hospital Universitario de Burgos. Servicio de Neurología
Burgos, Spain, 09006
Universitario de La Princesa; Servicio de Neurología
Madrid, Spain, 28006
Hospital Victoria Eugenia; Servico Neurología
Sevilla, Spain
Hospital Universitario la Fe; Servicio de Neurologia
Valencia, Spain, 46026
Complejo Hospitalario Zamora- H. Virgen de la Concha; Servicio Psiquiatria
Zamora, Spain, 49021
Spain, Alicante
Hospital General Universitario de Elche; Servicio de Neurología
Elche, Alicante, Spain, 03203
Spain, Barcelona
Hospital Mutua De Terrasa; Servicio de Neurologia
Terrasa, Barcelona, Spain, 08221
Spain, Caceres
Hospital Virgen del Puerto. Servicio de Neurología
Plasencia, Caceres, Spain, 10600
Spain, Guipuzcoa
Policlínica Guipuzcoa; Servicio de Neurología
Donostia, Guipuzcoa, Spain, 20014
Spain, Lerida
Hospital Universitario de Santa Maria; Servicio de Neurología
Lleida, Lerida, Spain, 25198
Spain, Madrid
Hospital Universitario de Getafe; Servicio de Geriatria
Getafe, Madrid, Spain, 28905
Hospital Quiron de Madrid; Servicio de Neurologia
Pozuelo de Alarcon, Madrid, Spain, 28223
Spain, Navarra
Clinica Universitaria de Navarra; Servicio de Neurología
Pamplona, Navarra, Spain, 31008
Spain, Vizcaya
CAE OROITU; Servicio de Neurología
Getxo, Vizcaya, Spain, 48993
Sweden
Skånes Universitetssjukhus Malmö, Minneskliniken
Malmoe, Sweden, SE-20502
Karolinska Uni Hospital, Huddinge; Dept. of Geriatric Med
Stockholm, Sweden, 14186
Turkey
Bezmialem Vakif Univ Medical
Istanbul, Turkey, 34286
Istanbul Bilim Sisli UTF
Istanbul, Turkey
Ondokuz Mayis Univ. Med. Fac.; Neurology
Samsun, Turkey, 55139
United Kingdom
Royal Cornhill Hospital; OAP Directorate
Aberdeen, United Kingdom, AB25 2ZH
Surrey and Borders NHS Foundation Trust; Brain Science Research Unit
Chertsey, United Kingdom, KT16 0AE
Sussex Partnership NHS Foundation Trust; Cognitive Treatment and Research unit
Crowborough, United Kingdom, TN6 1HB
NHS Lothian - Western General Hospital; NHS Lothian - Western General Hospital
Edinburgh, United Kingdom, EH4 2XU
Cross House Hospital
Kilmarnock, United Kingdom, KA2 0BE
Royal Liverpool and Broadgreen University Hospital Trust
L7 8xp, United Kingdom
RE:Cognition Health
London, United Kingdom, W1G 9RU
Charing Cross Hospital
London, United Kingdom, W6 8RF
Campus for Ageing and Vitality
Newcastle Upon Tyne, United Kingdom, NE4 6BE
Tees,Esk and Wear Valleys NHS Foundation Trust
North Yorkshire, United Kingdom, HG5 0UB
John Radcliffe Hospital
Oxford, United Kingdom, OX3 9DU
Derriford Hospital; Neurology
Plymouth, United Kingdom
Royal Preston Hospital
Preston, United Kingdom, PR2 9HT
Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom, S10 2JF
University Southampton NHS Foundation Trust; Wessex Neurologica Centre
Southampton, United Kingdom, SO166YD
University Hospital North Midlands
Stoke on Trent, United Kingdom, ST4 6QG
Re:Cognition Health Guildford
Surrey, United Kingdom, GU2 7YD
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services